Tags

Type your tag names separated by a space and hit enter

SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients.
J Clin Microbiol. 2020 10 21; 58(11)JC

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of COVID-19, resulting in cases of mild to severe respiratory distress and significant mortality. The global outbreak of this novel coronavirus has now infected >20 million people worldwide, with >5 million cases in the United States (11 August 2020). The development of diagnostic and research tools to determine infection and vaccine efficacy is critically needed. We have developed multiple serologic assays using newly designed SARS-CoV-2 reagents for detecting the presence of receptor-binding antibodies in sera. The first assay is surface plasmon resonance (SPR) based and can quantitate both antibody binding to the SARS-CoV-2 spike protein and blocking to the Angiotensin-converting enzyme 2 (ACE2) receptor in a single experiment. The second assay is enzyme-linked immunosorbent assay (ELISA) based and can measure competition and blocking of the ACE2 receptor to the SARS-CoV-2 spike protein with antispike antibodies. The assay is highly versatile, and we demonstrate the broad utility of the assay by measuring antibody functionality of sera from small animals and nonhuman primates immunized with an experimental SARS-CoV-2 vaccine. In addition, we employ the assay to measure receptor blocking of sera from SARS-CoV-2-infected patients. The assay is shown to correlate with pseudovirus neutralization titers. This type of rapid, surrogate neutralization diagnostic can be employed widely to help study SARS-CoV-2 infection and assess the efficacy of vaccines.

Authors+Show Affiliations

Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, USA.Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, USA.Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, USA.Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, USA.Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, USA.Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA.Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA dwkulp@wistar.org. Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32855181

Citation

Walker, Susanne N., et al. "SARS-CoV-2 Assays to Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients." Journal of Clinical Microbiology, vol. 58, no. 11, 2020.
Walker SN, Chokkalingam N, Reuschel EL, et al. SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients. J Clin Microbiol. 2020;58(11).
Walker, S. N., Chokkalingam, N., Reuschel, E. L., Purwar, M., Xu, Z., Gary, E. N., Kim, K. Y., Helble, M., Schultheis, K., Walters, J., Ramos, S., Muthumani, K., Smith, T. R. F., Broderick, K. E., Tebas, P., Patel, A., Weiner, D. B., & Kulp, D. W. (2020). SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients. Journal of Clinical Microbiology, 58(11). https://doi.org/10.1128/JCM.01533-20
Walker SN, et al. SARS-CoV-2 Assays to Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients. J Clin Microbiol. 2020 10 21;58(11) PubMed PMID: 32855181.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients. AU - Walker,Susanne N, AU - Chokkalingam,Neethu, AU - Reuschel,Emma L, AU - Purwar,Mansi, AU - Xu,Ziyang, AU - Gary,Ebony N, AU - Kim,Kevin Y, AU - Helble,Michaela, AU - Schultheis,Katherine, AU - Walters,Jewell, AU - Ramos,Stephanie, AU - Muthumani,Kar, AU - Smith,Trevor R F, AU - Broderick,Kate E, AU - Tebas,Pablo, AU - Patel,Ami, AU - Weiner,David B, AU - Kulp,Daniel W, Y1 - 2020/10/21/ PY - 2020/06/17/received PY - 2020/08/21/accepted PY - 2020/8/29/pubmed PY - 2020/11/5/medline PY - 2020/8/29/entrez KW - ACE2 blocking assay KW - COVID-19 KW - SARS-CoV-2 KW - SARS-CoV-2 immunity KW - SARS-CoV-2 vaccine KW - functional antibodies KW - serological tests JF - Journal of clinical microbiology JO - J Clin Microbiol VL - 58 IS - 11 N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of COVID-19, resulting in cases of mild to severe respiratory distress and significant mortality. The global outbreak of this novel coronavirus has now infected >20 million people worldwide, with >5 million cases in the United States (11 August 2020). The development of diagnostic and research tools to determine infection and vaccine efficacy is critically needed. We have developed multiple serologic assays using newly designed SARS-CoV-2 reagents for detecting the presence of receptor-binding antibodies in sera. The first assay is surface plasmon resonance (SPR) based and can quantitate both antibody binding to the SARS-CoV-2 spike protein and blocking to the Angiotensin-converting enzyme 2 (ACE2) receptor in a single experiment. The second assay is enzyme-linked immunosorbent assay (ELISA) based and can measure competition and blocking of the ACE2 receptor to the SARS-CoV-2 spike protein with antispike antibodies. The assay is highly versatile, and we demonstrate the broad utility of the assay by measuring antibody functionality of sera from small animals and nonhuman primates immunized with an experimental SARS-CoV-2 vaccine. In addition, we employ the assay to measure receptor blocking of sera from SARS-CoV-2-infected patients. The assay is shown to correlate with pseudovirus neutralization titers. This type of rapid, surrogate neutralization diagnostic can be employed widely to help study SARS-CoV-2 infection and assess the efficacy of vaccines. SN - 1098-660X UR - https://www.unboundmedicine.com/medline/citation/32855181/SARS_CoV_2_Assays_To_Detect_Functional_Antibody_Responses_That_Block_ACE2_Recognition_in_Vaccinated_Animals_and_Infected_Patients_ L2 - http://jcm.asm.org/cgi/pmidlookup?view=long&pmid=32855181 DB - PRIME DP - Unbound Medicine ER -